Pharmaceuticals company Divi's Laboratories has reported a standalone net profit of ₹883 crore, a record growth of 81% as compared to ₹488 crore profit during the same period last year.

The homegrown pharma major's revenue rose 46% to ₹2,546 crore in Q4 FY22 as compared to ₹1,741 crore during Q4 FY21, the company's stock exchange filing shows.

The expanse for the quarter on a standalone basis increased to ₹183 crore vs 164 crore during the quarter ending in March 2021.

For the fiscal year ending March 31, 2022, Divi's Laboratories earned a consolidated revenue of ₹9,074 crore against ₹7,032 crore during the previous year, reflecting a growth of 29%.

Profit before tax for the current year grew by 38% to ₹3,684 crore against a PBT of ₹2,666 crore for the previous year. Profit for the year amounted to ₹2,960 crore against a profit after tax (PAT) of ₹1,984 crore the last year, reflecting a growth of 49%.

The Hyderabad-headquartered company's forex gains for the quarter ending March 31, 2022, stand at ₹29 crore against ₹3 crore during the same quarter last year.

Divi Lab board has recommended a dividend of ₹30 per share of face value ₹2 each i.e., 1,500% for the financial year 2021-22, subject to the approval of members at the ensuing annual general meeting.

During the year 2021-22, the company has capitalised assets valuing ₹934.5 crore, while capital WIP (work in progress) at the year-end amounted to ₹469.9 crore.

The earnings per share (of ₹2 each) stood at ₹33.70 for the March 2022 quarter vs ₹33.99 for the previous quarter of the fiscal year.

Divi’s is the leading manufacturer of APIs (active pharmaceuticals ingredients), intermediates and registered starting materials offering high-quality products with the highest level of compliance and integrity to over 95 countries.

Amid the announcement of the financial result, the company's share is trading 0.78% or ₹33.70 up at ₹4,337.15 on the National Stock Exchange on Monday. The stock rose 3.01% in the past five days, while it dipped 1.54% in the past month. In the six-month or year-to-date period, the stock has given 8.84% and 6.65% of its value.

Divi Labs Q4

Divi Labs Q4 profit up 81% to ₹883 cr; revenue grows 46%